Antiretroviral pre-exposure prophylaxis does not enhance immune responses to HIV in exposed but uninfected persons

Journal of Infectious Diseases

Volumn 211, Issue 12, 2015, Pages 1943-1952

  Pattacini, Laura ^a   Murnane, Pamela M ^b   Baeten, Jared M ^b   Fluharty, Tayler R ^a   Thomas, Katherine K ^b   Bukusi, Elizabeth ^b,e   Katabira, Elly ^g   Mugo, Nelly ^b,f   Donnell, Deborah ^a,b   Lingappa, Jairam R ^b,c   Celum, Connie ^b   Marzinke, Mark ^d   McElrath, M Juliana ^a,b   Lund, Jennifer M ^a,b   Fife, Kenneth ^h   Were, Edwin ^h   Tumwesigye, Elioda ⁱ   Ndase, Patrick ^j   Ronald, Allan ^g   Cohen, Craig ^k   Wangisi, Jonathan ^l   Campbell, James ^l   Tappero, Jordan ^l   Kiarie, James ^j   Farquhar, Carey ^j   John Stewart, Grace ^j   Mugo, Nelly Rwamba ^j   more..

^a Fred Hutchinson Cancer Research Center   (United States)

^b Department of Global Health ^*  (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Centre for Microbiology Research   (United States)

^f KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^g MAKERERE UNIVERSITY   (Uganda)

^h INDIANA UNIVERSITY   (United States)

ⁱ Kabwohe Clinical Research Center   (Uganda)

^j UNIVERSITY OF WASHINGTON   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

more..

Author keywords

cellular immunity; HIV 1; prevention of sexual transmission; T lymphocyte

Indexed keywords

ANTIRETROVIRUS AGENT; CD39 ANTIGEN; CD45RA ANTIGEN; CD57 ANTIGEN; CD94 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; GAG PROTEIN; GAMMA INTERFERON; INDUCIBLE T CELL COSTIMULATOR; KI 67 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL1; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL3; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR; NATURAL KILLER CELL RECEPTOR NKG2A; NKB1 PROTEIN; NKG2C PROTEIN; PLACEBO; SIALIC ACID BINDING IMMUNOGLOBULIN LIKE LECTIN; SIGLEC 7 PROTEIN; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; ADENINE; DEOXYCYTIDINE; EMTRICITABINE; PHOSPHONIC ACID DERIVATIVE; TENOFOVIR;

ADULT; AFRICAN; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG BLOOD LEVEL; DRUG EFFICACY; FEMALE; HETEROSEXUAL FEMALE; HETEROSEXUAL MALE; HIGH RISK POPULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSTIMULATION; INFECTION PREVENTION; INNATE IMMUNITY; MALE; MYELOID DENDRITIC CELL; NATURAL KILLER CELL; PATIENT COMPLIANCE; PLASMACYTOID DENDRITIC CELL; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SERODIAGNOSIS; T LYMPHOCYTE ACTIVATION; AFRICA; ANALOGS AND DERIVATIVES; ANIMAL; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ADENINE; ADULT; AFRICA; ANIMALS; ANTI-RETROVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; EMTRICITABINE; FEMALE; HIV-1; HUMANS; MALE; ORGANOPHOSPHONATES; PLACEBOS; PRE-EXPOSURE PROPHYLAXIS; TENOFOVIR; YOUNG ADULT;

EID: 84930332067     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu815     Document Type: Article

References (34)

1. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34.
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
3. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
4. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2013; 381:2083-90.
5. Cranage M, Sharpe S, Herrera C, et al. Prevention of SIV rectal transmission and priming of T cell responses in macaques after local preexposure application of tenofovir gel. PLoS Med 2008; 5:e157.
6. Kersh EN, Adams DR, Youngpairoj AS, et al. T cell chemo-vaccination effects after repeated mucosal SHIV exposures and oral pre-exposure prophylaxis. PLoS One 2011; 6:e19295.
7. Mujugira A, Baeten JM, Donnell D, et al. Characteristics of HIV-1 serodiscordant couples enrolled in a clinical trial of antiretroviral preexposure prophylaxis for HIV-1 prevention. PLoS One 2011; 6:e25828.
8. Kahle EM, Hughes JP, Lingappa JR, et al. An empiric risk scoring tool for identifying high-risk heterosexual HIV-1-serodiscordant couples for targeted HIV-1 prevention. J Acquir Immune Defic Syndr 2013; 62:339-47.
9. Pattacini L, Murnane PM, Fluharty TR, et al. Enhanced and efficient detection of virus-driven cytokine expression by human NK and T cells. J Virol Methods 2014; 199C:17-24.
10. Li F, Malhotra U, Gilbert PB, et al. Peptide selection for human immunodeficiency virus type 1 CTL-based vaccine evaluation. Vaccine 2006; 24:6893-904.
11. Finak G, McDavid A, Chattopadhyay P, et al. Mixture models for singlecell assays with applications to vaccine studies. Biostatistics 2014; 15:87-101.
12. Alimonti JB, Kimani J, Matu L, et al. Characterization of CD8 T-cell responses in HIV-1-exposed seronegative commercial sex workers from Nairobi, Kenya. Immunol Cell Biol 2006; 84:482-5.
13. Kaul R, Dong T, Plummer FA, et al. CD8+ lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001; 107:1303-10.
14. Kaul R, Plummer FA, Kimani J, et al. HIV-1-specific mucosal CD8+ lymphocyte responses in the cervix of HIV-1-resistant prostitutes in Nairobi. J Immunol 2000; 164:1602-11.
15. Pala P, Serwanga J, Watera C, et al. Quantitative and qualitative differences in the T cell response to HIV in uninfected Ugandans exposed or unexposed to HIV-infected partners. J Virol 2013; 87:9053-63.
16. Restrepo C, Rallon NI, del Romero J, et al. Low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals. J Immunol 2010; 185:982-9.
17. Rowland-Jones S, Sutton J, Ariyoshi K, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1:59-64.
18. Rowland-Jones SL, Dong T, Dorrell L, et al. Broadly cross-reactive HIVspecific cytotoxic T-lymphocytes in highly-exposed persistently seronegative donors. Immunol Lett 1999; 66:9-14.
19. Carriere M, Lacabaratz C, Kok A, et al. HIV "elite controllers" are characterized by a high frequency of memory CD8+CD73+ T cells involved in the antigen-specific CD8+ T-cell response. J Infect Dis 2014; 9: 1321-30.
20. Turk G, Ghiglione Y, Falivene J, et al. Early Gag immunodominance of the HIV-specific T-cell response during acute/early infection is associated with higher CD8+ T-cell antiviral activity and correlates with preservation of the CD4+ T-cell compartment. J Virol 2013; 87:7445-62.
21. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990; 9:1551-60.
22. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-905.
23. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS. Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A 1990; 87:6058-62.
24. Pattacini L, Murnane PM, Kahle EM, et al. Differential regulatory T cell activity in HIV-1-exposed seronegative individuals. AIDS Res Hum Retroviruses 2013; 29:1321-9.
25. Miyara M, Yoshioka Y, Kitoh A, et al. Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911.
26. Alter G, Altfeld M. NK cell function in HIV-1 infection. Curr Mol Med 2006; 6:621-9.
27. Alter G, Altfeld M. Mutiny or scrutiny: NK cell modulation of DC function in HIV-1 infection. Trends Immunol 2011; 32:219-24.
28. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-40.
29. Alter G, Teigen N, Davis BT, et al. Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 2005; 106:3366-9.
30. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392:245-52.
31. Frahm N, DeCamp AC, Friedrich DP, et al. Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine. J Clin Invest 2012; 122:359-67.
32. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-20.
33. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366:1275-86.
34. Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIVinfected subjects. J Virol 2008; 82:5450-9.